Related references
Note: Only part of the references are listed.Istradefylline: First Global Approval
Rosselle Dungo et al.
DRUGS (2013)
Preladenant, a selective adenosine A2A receptor antagonist, is not associated with QT/QTc prolongation
Z. Wang et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Synthesis and Biological Evaluation of Metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535), A Potent Antagonist of the A(2A) Adenosine Receptor for the Treatment of Parkinson's Disease
Giovanni Piersanti et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Istradefylline, an adenosine A2A receptor antagonist, for patients with Parkinson's Disease: A meta-analysis
Wanqiang Chen et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2013)
Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease
Stewart A. Factor et al.
MOVEMENT DISORDERS (2013)
Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease
Yoshikuni Mizuno et al.
MOVEMENT DISORDERS (2013)
Adenosine A2A Antagonists in Parkinson's Disease: What's Next?
Patrick Hickey et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2012)
Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects
D. L. Cutler et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2012)
Adenosine A2A receptor in the monkey basal ganglia: Ultrastructural localization and colocalization with the metabotropic glutamate receptor 5 in the striatum
James W. Bogenpohl et al.
JOURNAL OF COMPARATIVE NEUROLOGY (2012)
Istradefylline for Parkinson's disease patients experiencing motor fluctuations: Results of the KW-6002-US-018 study
Emmanuelle Pourcher et al.
PARKINSONISM & RELATED DISORDERS (2012)
The Metabotropic Glutamate Receptor 4-Positive Allosteric Modulator VU0364770 Produces Efficacy Alone and in Combination with L-DOPA or an Adenosine 2A Antagonist in Preclinical Rodent Models of Parkinson's Disease
Carrie K. Jones et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Adenosine A2A Receptor Antagonists and Parkinson's Disease
Brian C. Shook et al.
ACS CHEMICAL NEUROSCIENCE (2011)
Population Pharmacokinetic Analysis of Istradefylline in Healthy Subjects and in Patients With Parkinson's Disease
William Knebel et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial
Robert A. Hauser et al.
LANCET NEUROLOGY (2011)
Milestones in Parkinson's Disease Therapeutics
Olivier Rascol et al.
MOVEMENT DISORDERS (2011)
Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease
Marie Therese Armentero et al.
PHARMACOLOGY & THERAPEUTICS (2011)
An Open-Label, Positron Emission Tomography Study to Assess Adenosine A(2A) Brain Receptor Occupancy of Vipadenant (BIIB014) at Steady-State Levels in Healthy Male Volunteers
David J. Brooks et al.
CLINICAL NEUROPHARMACOLOGY (2010)
Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders
Robert A. Hodgson et al.
EXPERIMENTAL NEUROLOGY (2010)
Quantification of Indirect Pathway Inhibition by the Adenosine A2a Antagonist SYN115 in Parkinson Disease
Kevin J. Black et al.
JOURNAL OF NEUROSCIENCE (2010)
Clinical Efficacy of Istradefylline (KW-6002) in Parkinson's Disease: A Randomized, Controlled Study
Yoshikuni Mizuno et al.
MOVEMENT DISORDERS (2010)
A long-term study of istradefylline in subjects with fluctuating Parkinson's disease
Stewart Factor et al.
PARKINSONISM & RELATED DISORDERS (2010)
Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial
H. H. Fernandez et al.
PARKINSONISM & RELATED DISORDERS (2010)
Novel investigational adenosine A2A receptor antagonists for Parkinson's disease
Annalisa Pinna
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Antagonists of the Human A2A Adenosine Receptor. 4. Design, Synthesis, and Preclinical Evaluation of 7-Aryltriazolo[4,5-d]pyrimidines
Roger J. Gillespie et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of Movement Disorders and Depression
Robert A. Hodgson et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
Proposed Neuroimaging Criteria for the Diagnosis of Multiple System Atrophy
David J. Brooks et al.
MOVEMENT DISORDERS (2009)
Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces Off' time in Parkinson's disease:: A double-blind, randomized, multicenter clinical trial (6002-US-005)
Peter A. LeWitt et al.
ANNALS OF NEUROLOGY (2008)
Evidence-Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease
Andrew J. Lees
CNS Neuroscience & Therapeutics (2008)
Adenosine A2A receptor antagonists and Parkinson's disease:: State of the art and future directions
N. Simola et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies
Reinaldo Naoto Takahashi et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Tremorolytic effects of adenosine A2A antagonists:: implications for parkinsonism
John D. Salamone et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Epidemiology of Parkinson's disease
Guido Alves et al.
JOURNAL OF NEUROLOGY (2008)
Study of Istradefylline in Patients with Parkinson's Disease on Levodopa with Motor Fluctuations
Robert A. Hauser et al.
MOVEMENT DISORDERS (2008)
A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease
M. Stacy et al.
NEUROLOGY (2008)
Positron emission tomography analysis of [11C]KW-6002 binding to human and rat adenosine A2A receptors in the brain
D. J. Brooks et al.
SYNAPSE (2008)
Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry -: Implications for drug addiction, sleep and pain
S. Ferre et al.
PROGRESS IN NEUROBIOLOGY (2007)
The neuroprotective effects of caffeine -: A prospective population study (the Three City Study)
K. Ritchie et al.
NEUROLOGY (2007)
Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease
Annalisa Pinna et al.
SYNAPSE (2007)
Characterization of the antiparkinsoni an effects of the new adenosine A2A receptor antagonist ST1535:: Acute and subchronic studies in rats
Elisabetta Tronci et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
Potent, selective, and orally active adenosine A2A receptor antagonists:: Arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines
Bernard R. Neustadt et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2007)
The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose Of L-dopa in unilaterally 6-OHDA-lesioned rats
Sarah Rose et al.
BRAIN RESEARCH (2007)
Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease
M. Horstink et al.
EUROPEAN JOURNAL OF NEUROLOGY (2006)
Novel neuroprotection by caffeine and adenosine A2A receptor antagonists in animal models of Parkinson's disease
Anti Kalda et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2006)
ST 1535:: A preferential A2A adenosine receptor antagonist
Maria Antonietta Stasi et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2006)
The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets
Sarah Rose et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2006)
Non-motor symptoms of Parkinson's disease: diagnosis and management
KR Chaudhuri et al.
LANCET NEUROLOGY (2006)
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists.: Design, synthesis, and pharmacological characterization
P Minetti et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease
P Jenner
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2005)
Evidence-based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004
CG Goetz et al.
MOVEMENT DISORDERS (2005)
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial
O Rascol et al.
LANCET (2005)
Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease
K Xu et al.
PHARMACOLOGY & THERAPEUTICS (2005)
Levodopa in the treatment of Parkinson's disease: Current controversies
CW Olanow et al.
MOVEMENT DISORDERS (2004)
A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease
F Bibbiani et al.
EXPERIMENTAL NEUROLOGY (2003)
Adenosine A2A receptor antagonist treatment of Parkinson's disease
W Bara-Jimenez et al.
NEUROLOGY (2003)
Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD
RA Hauser et al.
NEUROLOGY (2003)
Staging of brain pathology related to sporadic Parkinson's disease
H Braak et al.
NEUROBIOLOGY OF AGING (2003)
Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of L-DOPA-induced dyskinesia
M Lundblad et al.
JOURNAL OF NEUROCHEMISTRY (2003)
Adenosine A2A receptors inhibit the N-methyl-D-aspartate component of excitatory synaptic currents in rat striatal neurons
Z Gerevich et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
In vivo labelling of the adenosine A2A receptor in mouse brain using the selective antagonist [3H]SCH 58261
M El Yacoubi et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2001)
Adenosine A2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats
K Koga et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2000)
Pathophysiology of the basal ganglia in Parkinson's disease
JA Obeso et al.
TRENDS IN NEUROSCIENCES (2000)
Combined use of the adenosine A2A antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys
T Kanda et al.
EXPERIMENTAL NEUROLOGY (2000)
Share Paper
